{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T01:33:38Z","timestamp":1721698418385},"reference-count":23,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1997,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interleukin-2 (IL-2) gene therapy alone and in combination with the herpes thymidine kinase gene (tk) was used to evaluate immunological responses and antitumor effects in head and neck cancer. Established floor of mouth squamous cell carcinomas in C3H\/HeJ mice were directly injected with recombinant adenoviral vectors carrying both therapeutic and control genes. One week after adenoviral gene transfer, only the animals treated with combination IL-2+tk or tk alone demonstrated significant tumor regression. Residual tumors were harvested for microscopic evaluation and immunohistochemistry staining, which revealed a predominance of CD8+ lymphocytes in the tumor beds of the animals treated with IL-2. To evaluate the systemic immune effects of IL-2, animals treated with single or combination gene therapy received a second site challenge with parental tumor cells or a heterologous but syngeneic sarcoma cell line. Mice treated with combination IL-2 and tk demonstrated a protective systemic immunity specific to the parental tumor cell line, whereas no systemic immune response was evident in mice receiving IL-2 alone. In a separate experiment, a range of concentrations of the adenovirus IL-2 vector were used to treat established tumors. Even with the maximal single-dose adenovirus concentration, IL-2 alone was ineffective as a single therapy. These results support the use of adenovirus-mediated gene transfer of IL-2 as an effective immunotherapy when used adjuvantly with the tk \u201csuicide gene\u201d.<\/jats:p>","DOI":"10.1210\/mend.11.6.0012","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T17:29:33Z","timestamp":1389202173000},"page":"667-673","source":"Crossref","is-referenced-by-count":10,"title":["The Role of Interleukin-2 in Combination Adenovirus Gene Therapy for Head and Neck Cancer"],"prefix":"10.1210","volume":"11","author":[{"suffix":"Jr.","given":"Bert W.","family":"O\u2019Malley","sequence":"first","affiliation":[{"name":"Department of Otolaryngology \u2014 Head & Neck Surgery (B.W.O., D.A.S., D.L., L.D), Johns Hopkins University, Baltimore, Maryland 21203,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duane A.","family":"Sewell","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2014 Head & Neck Surgery (B.W.O., D.A.S., D.L., L.D), Johns Hopkins University, Baltimore, Maryland 21203,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daqing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2014 Head & Neck Surgery (B.W.O., D.A.S., D.L., L.D), Johns Hopkins University, Baltimore, Maryland 21203,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichiro","family":"Kosai","sequence":"additional","affiliation":[{"name":"Department of Pathology (K.-i.K.), Osaka University Medical Center, Osaka 565, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Hsia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cell Biology (S.L.C.W., S.-H.C.), Baylor College of Medicine, Houston, Texas 77030,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savio L.C.","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Cell Biology (S.L.C.W., S.-H.C.), Baylor College of Medicine, Houston, Texas 77030,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2014 Head & Neck Surgery (B.W.O., D.A.S., D.L., L.D), Johns Hopkins University, Baltimore, Maryland 21203,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071615531385700_R1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0092-8674(90)90591-2","article-title":"Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.","volume":"60","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"2020071615531385700_R2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N Engl J Med"},{"key":"2020071615531385700_R3","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM198704093161502","article-title":"Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.","volume":"316","author":"West","year":"1987","journal-title":"N Engl J Med"},{"key":"2020071615531385700_R4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from normal human bone marrow.","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"key":"2020071615531385700_R5","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.4049\/jimmunol.126.6.2321","article-title":"Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity.","volume":"126","author":"Kuribayashi","year":"1981","journal-title":"J Immunol"},{"key":"2020071615531385700_R6","first-page":"565","article-title":"Cytotoxic responses: the regulatory influence of interleukin-2.","volume":"14","author":"Henney","year":"1982","journal-title":"Transplant Proc"},{"key":"2020071615531385700_R7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/291335a0","article-title":"Interleukin-2 augments natural killer cell activity.","volume":"291","author":"Henney","year":"1981","journal-title":"Nature"},{"key":"2020071615531385700_R8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI110981","article-title":"Interleukin-2 enhances the depressed natural killer and cytomegalo-virus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.","volume":"72","author":"Rook","year":"1983","journal-title":"J Clin Invest"},{"key":"2020071615531385700_R9","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM198704093161502","article-title":"Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.","volume":"316","author":"West","year":"1987","journal-title":"N Engl J Med"},{"key":"2020071615531385700_R10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0167-5699(93)90051-L","article-title":"Cancer vaccines.","volume":"14","author":"Pardoll","year":"1993","journal-title":"Immunol Today"},{"key":"2020071615531385700_R11","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1084\/jem.172.4.1217","article-title":"Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.","volume":"172","author":"Gansbacher","year":"1990","journal-title":"J Exp Med"},{"key":"2020071615531385700_R12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.1948050","article-title":"Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.","volume":"254","author":"Golumbek","year":"1991","journal-title":"Science"},{"key":"2020071615531385700_R13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00002371-199603000-00005","article-title":"Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: clinical and pathologic correlations.","volume":"19","author":"De Stefani","year":"1996","journal-title":"J Immunother"},{"key":"2020071615531385700_R14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0959-437X(93)90126-A","article-title":"Gene therapy: adenovirus vectors.","volume":"3","author":"Kozarsky","year":"1993","journal-title":"Curr Opin Gen Dev"},{"key":"2020071615531385700_R15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1089\/hum.1994.5.5-615","article-title":"Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity.","volume":"5","author":"Boucher","year":"1994","journal-title":"Hum Gene Ther"},{"key":"2020071615531385700_R16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0092-8674(92)90213-V","article-title":"In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.","volume":"68","author":"Rosenfeld","year":"1992","journal-title":"Cell"},{"key":"2020071615531385700_R17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.1993.4.4-461","article-title":"Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis.","volume":"4","author":"Rich","year":"1993","journal-title":"Hum Gene Ther"},{"key":"2020071615531385700_R18","first-page":"209","article-title":"Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in nasal epithelium.","volume":"5","author":"Welsh","year":"1994"},{"key":"2020071615531385700_R19","first-page":"1080","article-title":"Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model.","volume":"55","author":"O\u2019Malley Jr","year":"1995","journal-title":"Cancer Res"},{"key":"2020071615531385700_R20","first-page":"1737","article-title":"Combination Gene Therapy for Oral Cancer in a Murine Model.","volume":"56","author":"O\u2019Malley Jr","year":"1996","journal-title":"Cancer Res"},{"key":"2020071615531385700_R21","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1073\/pnas.92.7.2577","article-title":"Combination gene therapy for liver metastasis of colon carcinoma in vivo.","volume":"92","author":"Chen","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071615531385700_R22","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1073\/pnas.91.8.3054","article-title":"Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer.","volume":"91","author":"Chen","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071615531385700_R23","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/0360-3016(84)90371-7","article-title":"Modification of the effects of continuous low dose irradiation by concurrent chemotherapy infusion.","volume":"10","author":"Fu","year":"1984","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Molecular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mend\/article-pdf\/11\/6\/667\/8954069\/mend0667.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/mend\/article-pdf\/11\/6\/667\/8954069\/mend0667.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T15:01:56Z","timestamp":1688914916000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mend\/article\/11\/6\/667\/2754439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,6,1]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1997,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/mend.11.6.0012","relation":{},"ISSN":["0888-8809","1944-9917"],"issn-type":[{"value":"0888-8809","type":"print"},{"value":"1944-9917","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,6,1]]}}}